Imaging of multidrug resistance in cancer

Cancer Imaging

Volumn 11, Issue 1, 2011, Pages 1-8

  Dizdarevic, Sabina ^a,b   Peters, A M ^a,b  

^a Worthing Hospital   (United Kingdom)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

ABC transporters; Cancer; Imaging; Multidrug resistance; P glycoprotein

Indexed keywords

ABC TRANSPORTER; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; TECHNETIUM 99M; VASCULOTROPIN;

BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER RESISTANCE; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; GENETIC DIFFERENCE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VIVO STUDY; MOLECULAR IMAGING; MULTIDRUG RESISTANCE; PHOTON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SCINTIGRAPHY; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPY EFFECT; TREATMENT RESPONSE;

ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, NEOPLASM; GENES, MDR; GENOTYPE; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; RADIONUCLIDE IMAGING; TECHNETIUM TC 99M SESTAMIBI;

EID: 79959616620     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2011.0001     Document Type: Review

References (51)

1. Nagengast W, Oude Munnink T, Dijkers E, et al. editor. Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets. Methods Mol Biol 2010; 596: 15-31. doi:10.1007/978-1-60761-416-6- 2. PMid: 19949918.
2. Lockhart A, Tirona L, Kim R. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2003; 2: 685-98. PMid:12883042.
3. Leslie E, Deeley R, Cole S. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 1: 216-37. (Pubitemid 40552845)
4. Sharom F. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105-27. doi:10.2217/14622416.9.1.105. PMid:18154452.
5. Aller S, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323: 1718-22. doi:10.1126/science.1168750. PMid:19325113.
6. Piwnica-Worms D, Chiu M, Budding M, Kronauge J, Kramer R, Croop J. Functional imaging of multidrug-resistant p-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-84. PMid:8094997. (Pubitemid 23087894)
7. Sailaja K, Surekha D, Nageswara Rao D, Raghunadha Rao D, Vishnupriya S. ABCB1 (MDR1, P-glycoprotein) C3435T gene polymorphism and its possible association with chronic myeloid leukemia prognosis. Curr Trends Biotechnol Pharmacy 2008; 2: 514-22.
8. Mizutani T, Masuda M, Nakai E, et al. Genuine functions of Pglycoprotein (ABCB1). Curr Drug Metab 2008; 9: 167-74. doi:10.2174/138920008783571756. PMid:18288958.
9. Chaudhary P, Mechetner E, Roninson I. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 11: 2735-9.
10. Fromm M. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 2002; 27: 299-303. (Pubitemid 36015717)
11. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-74. doi:10.1067/mcp.2001.114164. PMid:11240981.
12. Jamroziak K, Mlynarski W, Balcerczak E, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314-21. doi:10.1111/j.1600-0609.2004.00228.x. PMid:15059065.
13. Sigesmund M, Brinkmann U, Schaffeler E, et al. Association of the P-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumours. J Am Soc Nephrol 2002; 13: 1847-54. doi:10.1097/01.ASN.0000019412.87412.BC. (Pubitemid 34700609)
14. Seo T, Ishitsu T, Ueda N, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 2006; 7: 551-61. doi:10.2217/14622416.7.4.551. PMid:16753003.
15. Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358: 383-4. doi:10.1016/S0140-6736(01)05579-9. PMid: 11502320.
16. Shukla S, Wu C, Ambudkar S. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 2008; 4: 205-23. doi:10.1517/17425255.4.2.205. PMid:18248313.
17. Ghibellini G, Vasist L, Heizer W, Kowalsky R, Brouwer K. Quantitation of Tc-99m-sestamibi bibliary exretion in humans. Clin Pharmacol Therapeutics 2005; 79: 19. doi:10.1016/j.clpt.2005.12.069.
18. 99mTc-tetrofosmin for functional imaging of P-glycoprotein modulation in vivo. J Clin Pharmacol 2001:39-47.
19. Bigott H, Prior J, Piwnica-Worms D, Welch M. Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi. Mol Imaging 2005; 4: 30-9. PMid:15967124. (Pubitemid 43026015)
20. Kannan P, John C, Zoghbi S, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 2009; 86: 368-77. doi:10.1038/clpt.2009.138. PMid:19625998.
21. 11C-verapamil in the brain: studies of healthy humans. J Nucl Med 2009; 50: 1267-75. doi:10.2967/jnumed.108.059162. PMid:19617341.
22. 68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 2005; 46: 354-64. PMid: 15695797.
23. 18F]Fluoropaclitaxel. Molecular Imaging and Contrast Agent Database [Internet]]; 2006.
24. Bauer F, Mairinger S, Dorner B, et al. Synthesis and mPET of the radiolabelled P-glycoprotein inhibitor 11-C-tariquidar. Eur J Nucl Med Mol Imaging 2009; 36: S222.
25. Piwnica-Worms D, Kronauge J, Chiu M. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation 1190; 82: 1826-38. PMid:2225379.
26. 99Tc-NMR spectroscopy. Magn Reson Imaging 1994; 12: 641-52. doi:10.1016/0730- 725X(94)92459-7. PMid:8057769.
27. Kabasakal L, Halac M, Nisli C. The effect of P-glycoprotein function inhibition with cyclosporine A on the biodistribution of Tc-99m-sestamibi. Clin Nucl Med 2000; 25: 20-3. doi:10.1097/00003072-200001000-00005. PMid:10634525.
28. 99mTc]-hexakis-2-methoxyisobutyl isonitrile in tumour cells and its modulation by lipophilic P-glycoprotein ligands. Eur J Pharm Sci 2005; 25: 201-9. PMid:15911215.
29. 201Tl-thallous chloride in tumour cells: role of P-glycoprotein. Q J Nucl Med 1995; 39: 122-8. PMid: 8574806.
30. Joseph D, Bhargava K, Malhi H. Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes. Eur J Nucl Med Mol Imaging 2003; 30: 1024-31. doi:10.1007/s00259-002-1111-z. PMid:12536246.
31. Koomaji R, Stammler G, Manegold C, Mattern J, Volm M. Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer. Cancer Lett 1996; 110: 129-136. doi:10.1016/S0304-3835(96)04471-0. (Pubitemid 27042931)
32. Chen C, Meadows B, Regis J, et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res 1997; 3: 545-52. PMid:9815718. (Pubitemid 27211831)
33. Luker G, Fracasso P, Dobkin J, Piwnica-Worms D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J Nucl Med 1997; 38: 369-72. PMid:9074520. (Pubitemid 27376885)
34. Casalta-Lopez J, Abrantes A, Rio J, et al. MDR and MDR reversal kinetics in humana adenocarcinoma cell lines. Eur J Nucl Med Mol Imaging 2009; 36: S242.
35. Vecchio S, Zannetti A, Salvatore B, Paone G, Fonti R, Salvatore M. Functional imaging of multidrug resistance in breast cancer. Phys Med 2006; 21: 24-7. doi:10.1016/S1120-1797(06)80019-0. PMid:17645989.
36. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-83. PMid:9586878. (Pubitemid 28234709)
37. Mubashar M, Harrington K, Chaudhary K, et al. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med 2002; 43: 519-25. PMid:11937596. (Pubitemid 34286348)
38. 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med 2009; 50: 376-81. doi:10.2967/jnumed.108. 055988. PMid:19223414.
39. 99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors. Nucl Med Commun 2007; 28: 888-94. doi:10.1097/MNM.0b013e3282f1646c. PMid: 18090213.
40. Sasajima T, Shimada N, Naitoh Y, et al. 99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors. Int J Cancer 2007; 121: 2637-45. doi:10.1002/ijc.23011. PMid:17708555.
41. 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer. Clin Cancer Res 2004; 10: 3788-93. doi:10.1158/1078-0432.CCR-1072-3. PMid:15173086.
42. Mubashar M, Harrington K, Chaudhary K, Lalani eN, Stamp G, Peters A. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines. Acta Oncol 2004; 43: 443-52. doi:10.1080/02841860410031048. PMid:15360048.
43. 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1281-5. PMid: 15112342.
44. Kostakoglu L. Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet? Clin Lymphoma 2002; 2: 242-8. doi:10.3816/CLM.2002.n.006. PMid:11970764.
45. Chen Y, Wang W, Chan T, Sun S, Kao A. A review of the costeffectiveness of Tc-99m sestamibi scintimammography in diagnosis of breast cancer in Taiwanese women with indeterminate mammographically dense breast. Surg Oncol 2002; 11: 151-5. doi:10.1016/S0960-7404(02)00030-0. PMid:12356511.
46. Giovanella L, Suriano S, Maffioli M, Ceriani L, Spriano G. (99m)Tc-sestamibi scanning in thyroid nodules with nondiagnostic cytology. Head Neck 2010; 32: 607-11. PMid:19693945.
47. 99mTc-MIBI imaging in the presurgical characterization of thyroid follicular neoplasms: relationship to multidrug resistance protein expression. J Nucl Med 2009; 50: 1785-93. doi:10.2967/jnumed.109.064980. PMid:19837765.
48. 99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma. Q J Nucl Med Mol Imaging 2005; 49: 281-5. PMid:16172574.
49. Wong M, Evans S, Rivory L, et al. Hepatic technetium Tc 99mlabeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 2005; 77: 33-42. doi:10.1016/j.clpt.2004.09.002. PMid:15637529.
50. Koziolek M, Riess R, Geiger H, Thevenod F, Hauser I. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2003; 60: 156-66. doi:10.1046/j.1523-1755.2001. 00782.x. PMid: 11422747.
51. Lee C. Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 2010; 596: 325-40. doi:10.1007/978-1-60761-416-6-14. PMid:19949930.